A major new report brings much-needed relief to the global cancer community, revealing that advanced cancer diagnoses in the United States—which spiked during the early days of the COVID-19 pandemic—have now returned to levels seen before the global crisis. Published Monday in the journal Cancer, the study offers a broad analysis of U.S. cancer statistics, addressing widespread fears that disruptions to screening during the pandemic would drive a lasting increase in late-stage cancer cases and, ultimately, higher death rates (AP News).
This research matters to Thai readers for several reasons. First, cancer is the leading cause of death in Thailand, responsible for over 80,000 deaths annually, with breast, cervical, liver, and colon cancers among the most common. Early detection is key to improving survival, especially in a country where access to screening programs is not yet universal—many Thais skipped annual checkups during the pandemic, echoing global concerns. The report provides insight not only into what happened in the U.S., but also guidance for policymakers and the public in Thailand seeking reassurance as healthcare seeks to “catch up” in a post-COVID world.
Early in 2020, as hospitals struggled to cope with surges of COVID-19 patients, millions of Americans—and countless Thais—delayed routine screenings such as colonoscopies, mammograms, and lung scans. Initial data raised alarm: a higher percentage of cancers were diagnosed at more advanced stages in 2020, raising the specter of more aggressive, less treatable disease down the road. However, the new U.S. report—produced by the North American Association of Central Cancer Registries and major health agencies—finds that by 2021, the proportion of advanced cancer diagnoses had, reassuringly, reverted to pre-pandemic levels for most cancer types. As Recinda Sherman, the study’s lead author, told the Associated Press, “So far, we haven’t seen an excess of late-stage diagnoses,” making it unlikely that cancer mortality will spike as a result of disrupted care. “It is very reassuring,” Sherman added.
The same pattern appeared in overall cancer incidence: new diagnoses dropped in 2020 as people avoided hospitals and clinics, but rebounded in 2021 as healthcare systems adapted and patients returned. Importantly, trends were remarkably consistent across different states, regardless of variations in COVID-related policy restrictions. This suggests that individual behaviors and local hospital protocols played a greater role in cancer care disruption than government-mandated closures per se.
Late-stage diagnoses in cervical and prostate cancer did tick upward in 2021, but researchers called these increases “not large”—a subtlety Thai health professionals should heed, given the country’s ongoing challenges with cervical screening, especially in rural areas. The study stops at 2021, so researchers caution that longer-term surveillance is needed to confirm these trends. Health experts stress that continued delays beyond 2021 or emerging aggressive disease types might yet shift the picture, albeit the current data is optimistic.
According to Dr. Vorasith Charoensiri, an oncologist at King Chulalongkorn Memorial Hospital, “This U.S. data is very encouraging and mirrors what we are beginning to see in some Thai hospitals—a dip in diagnosis at the pandemic’s peak, then a quick rebound. It underscores how resilient the cancer care system can be when screening services and patient confidence return.” An American Cancer Society spokesperson echoed this sense of optimism, citing the study’s “broadest yet” analysis and underscoring the unique collaboration of multiple national agencies.
For Thailand, the findings have multiple implications. While the U.S. system benefitted from broad-based cancer registries and rapid adaptation in healthcare access, Thailand’s Universal Coverage Scheme (UCS) and National Cancer Registry Program offer similar structural advantages, particularly in urban and large provincial settings. However, disparities remain: in remote parts of the Northeast and deep South, barriers to screening, such as lack of transport and public awareness, could mean that local rebounds in early detection may lag behind what’s been tracked in the U.S.—a point Thai policymakers and local administrative organizations must address.
Culturally, many Thai people rely on family members to prompt routine health visits, and some Buddhist teachings prioritize acceptance over aggressive intervention. During the pandemic, fear of infection, misinformation, and resource scarcity contributed to missed appointments—yet the high value Thai society places on community and the quick resumption of lifestyle after lockdowns might explain why patients returned to clinics rapidly once perceived risks declined, paralleling findings in the U.S.
It is significant that cancer death rates in the U.S. have continued to decline through the pandemic, a trend with parallels in advanced Asian health systems. According to the American Cancer Society, ongoing improvements in early detection technology and more equitable treatment access have likely offset temporary setbacks (American Cancer Society). For Thailand, this highlights the critical importance of restoring public confidence in routine health services and ramping up “screening catch-up” activities for populations that missed exams during the pandemic years.
Looking forward, Thai oncologists and health officials should closely watch ongoing cancer registry data to identify any delayed spikes in advanced cancer presentation, particularly for harder-to-screen populations. Efforts to enhance public outreach, especially using community health volunteers (อสม.), can help keep Thailand’s cancer deaths on a downward trend. National Cancer Institute of Thailand guidance aligns with this, encouraging a focus on public education, targeted mobile screening programs in rural areas, and the integration of telemedicine consults to overcome lingering access challenges (National Cancer Institute Thailand).
In summary, while Thailand’s healthcare system faced substantial disruption during COVID-19, this reassuring U.S. study provides evidence that with rapid restoration of screening services and robust public health communication, the feared wave of advanced cancers and excess deaths may not materialize. The Thai public should be encouraged by this global evidence, but also motivated to resume regular cancer screenings and support community awareness efforts.
For practical action: Thai readers are urged to schedule catch-up screenings if any were missed between 2020 and 2022—especially for breast, cervical, colon, and prostate cancer. Healthcare providers should redouble outreach to vulnerable populations, and policymakers must prioritize investment in both data-tracking and grassroots education. In true “Thai-style,” by combining updated medical practice with the power of community, Thailand can ensure a compassionate, equitable response to cancer in the wake of the pandemic.
Sources: